CFZ533
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Sjögren Syndrome
Conditions
Sjögren Syndrome
Trial Timeline
Oct 1, 2019 → Jun 6, 2023
NCT ID
NCT03905525About CFZ533
CFZ533 is a phase 2 stage product being developed by Novartis for Sjögren Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT03905525. Target conditions include Sjögren Syndrome.
What happened to similar drugs?
0 of 8 similar drugs in Sjögren Syndrome were approved
Approved (0) Terminated (1) Active (7)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04129528 | Phase 2 | Completed |
| NCT03905525 | Phase 2 | Completed |
| NCT02713256 | Phase 2 | Completed |
Competing Products
20 competing products in Sjögren Syndrome